These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72 related articles for article (PubMed ID: 16563568)
1. The leukocyte expression of CD36 is low in patients with Alzheimer's disease and mild cognitive impairment. Giunta M; Rigamonti AE; Scarpini E; Galimberti D; Bonomo SM; Venturelli E; Müller EE; Cella SG Neurobiol Aging; 2007 Apr; 28(4):515-8. PubMed ID: 16563568 [TBL] [Abstract][Full Text] [Related]
2. Menopausal transition: a possible risk factor for brain pathologic events. Bonomo SM; Rigamonti AE; Giunta M; Galimberti D; Guaita A; Gagliano MG; Müller EE; Cella SG Neurobiol Aging; 2009 Jan; 30(1):71-80. PubMed ID: 17601638 [TBL] [Abstract][Full Text] [Related]
3. CD36 overexpression in human brain correlates with beta-amyloid deposition but not with Alzheimer's disease. Ricciarelli R; D'Abramo C; Zingg JM; Giliberto L; Markesbery W; Azzi A; Marinari UM; Pronzato MA; Tabaton M Free Radic Biol Med; 2004 Apr; 36(8):1018-24. PubMed ID: 15059642 [TBL] [Abstract][Full Text] [Related]
4. Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease. Kim TS; Lim HK; Lee JY; Kim DJ; Park S; Lee C; Lee CU Neurosci Lett; 2008 May; 436(2):196-200. PubMed ID: 18378084 [TBL] [Abstract][Full Text] [Related]
5. Adenosine A2A receptor expression in peripheral blood mononuclear cells of patients with mild cognitive impairment. Arosio B; Viazzoli C; Mastronardi L; Bilotta C; Vergani C; Bergamaschini L J Alzheimers Dis; 2010; 20(4):991-6. PubMed ID: 20413899 [TBL] [Abstract][Full Text] [Related]
6. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine. Blasko I; Jellinger K; Kemmler G; Krampla W; Jungwirth S; Wichart I; Tragl KH; Fischer P Neurobiol Aging; 2008 Jan; 29(1):1-11. PubMed ID: 17055615 [TBL] [Abstract][Full Text] [Related]
7. Frontal white matter volume and delta EEG sources negatively correlate in awake subjects with mild cognitive impairment and Alzheimer's disease. Babiloni C; Frisoni G; Steriade M; Bresciani L; Binetti G; Del Percio C; Geroldi C; Miniussi C; Nobili F; Rodriguez G; Zappasodi F; Carfagna T; Rossini PM Clin Neurophysiol; 2006 May; 117(5):1113-29. PubMed ID: 16564740 [TBL] [Abstract][Full Text] [Related]
12. Multivariate deformation-based analysis of brain atrophy to predict Alzheimer's disease in mild cognitive impairment. Teipel SJ; Born C; Ewers M; Bokde AL; Reiser MF; Möller HJ; Hampel H Neuroimage; 2007 Oct; 38(1):13-24. PubMed ID: 17827035 [TBL] [Abstract][Full Text] [Related]
13. Plasma aminothiol compounds, but not serum tumor necrosis factor receptor II and soluble receptor for advanced glycation end products, are related to the cognitive impairment in Alzheimer's disease and mild cognitive impairment patients. Hernanz A; De la Fuente M; Navarro M; Frank A Neuroimmunomodulation; 2007; 14(3-4):163-7. PubMed ID: 18073509 [TBL] [Abstract][Full Text] [Related]
14. Expression of inducible nitric oxide synthase (iNOS) and period 1 (PER1) clock gene products in different sleep stages of patients with cognitive impairment. Tseng IJ; Liu HC; Yuan RY; Sheu JJ; Yu JM; Hu CJ J Clin Neurosci; 2010 Sep; 17(9):1140-3. PubMed ID: 20541418 [TBL] [Abstract][Full Text] [Related]
15. Oxidative inactivation of the proteasome in Alzheimer's disease. Cecarini V; Ding Q; Keller JN Free Radic Res; 2007 Jun; 41(6):673-80. PubMed ID: 17516240 [TBL] [Abstract][Full Text] [Related]